C-CAR168
Asset
Autologous CAR T cells target CD20- and BCMA-expressing cells to deplete pathogenic B cells and plasma cells.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- TNFRSF17
- 6
- Indications
- 1
- Trial
- 1
- Developer
Indications
6Autoimmune
Phase 1, Not yet recruiting, NCT07825389, clinicaltrials.gov, Oct 16, 2026
MS
Phase 1, Not yet recruiting, NCT07825389, clinicaltrials.gov, Oct 16, 2026
Multiple sclerosis
Phase 1, Not yet recruiting, NCT07825389, clinicaltrials.gov, Oct 16, 2026
3 more
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.